Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC
16 Apr 2024
Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC
Urinary markers in the surveillance setting of non-muscle invasive bladder cancer
Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC
EAU 2024: Bladder cancer latest